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Background: PIN2/TRF1-interacting telomerase inhibitor1 (PinX1) was recently suggested as a putative tumor
suppressor in several types of human cancer, based on its binding to and inhibition of telomerase. Moreover, loss
of PinX1 has been detected in many human malignancies. However, the possible involvement of PinX1 and its
clinical/prognostic significance in urothelial carcinoma of the bladder (UCB) are unclear.
Methods: The PinX1 expression profile was examined by quantitative real-time polymerase chain reaction (qRT-PCR),
western blotting, and immunohistochemistry (IHC) in UCB tissues and adjacent normal urothelial bladder epithelial
tissues. PinX1 was overexpressed and silenced in UCB cell lines to determine its role in tumorigenesis, development of
UCB, and the possible mechanism.
Results: PinX1 expression in UCB was significantly down-regulated at both mRNA and protein level as compared with
that in normal urothelial bladder epithelial tissues. PinX1 levels were inversely correlated with tumor multiplicity, advanced
N classification, high proliferation index (Ki-67), and poor survival (P < 0.05). Moreover, overexpression of PinX1 in UCB
cells significantly inhibited cell proliferation in vitro and in vivo, whereas silencing PinX1 dramatically enhanced cell
proliferation. Overexpression of PinX1 resulted in G1/S phase arrest and cell growth/proliferation inhibition, while silencing
PinX1 led to acceleration of G1/S transition, and cell growth/proliferation promotion by inhibiting/enhancing telomerase
activity and via the p16/cyclin D1 pathway.
Conclusions: These findings suggest that down-regulation of PinX1 play an important role in the tumorigenesis and
development of UCB and that the expression of PinX1 as detected by IHC is an independent molecular marker in patients
with UCB.
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Urothelial carcinoma of the bladder (UCB) is one of the
major causes of morbidity and mortality in Western coun-
tries [1]. Clinically, radical cystectomy (RC) remains the
most common treatment for patients with muscle-invasive
UCB or for patients with superficial disease that is at high* Correspondence: zhoufj@sysucc.org.cn; xied@mail.sysu.edu.cn
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reproduction in any medium, provided the orrisk of recurrence and progression. Despite advancement
of the surgical technique and the development of novel
drugs [2,3], approximately 35% of UCB patients will re-
lapse after treatment, and 5-year cancer-specific survival
remains at only 50-60% [4]. It is known that the pathogen-
esis of UCB is a multistep process that involves multiple
genetic changes, including loss of tumor suppressor genes
and activation of oncogenes [5]. Although the molecular
and/or genetic alterations of UCB have been widely stud-
ied, the discovery of specific molecular markers that are
present in UCB cells that could serve as reliable clinical/
prognostic factors remains substantially limited to date.This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is a newly cloned gene mapped to chromosome 8p23.1
that consists of seven exons in humans and is a region
frequently associated with loss of heterozygosity in a var-
iety of human malignancies [6-10]. PinX1 has been iden-
tified as a critical component in regulating telomerase
activity, and is proposed to be a putative tumor suppres-
sor [11]. In humans, ectopic overexpression of PinX1
leads to a decrease in both telomerase activity and can-
cer cell tumorigenicity, whereas suppression of PinX1
expression results in an increase in both telomerase ac-
tivity and cancer cell tumorigenicity [11]. Very recently,
Chang et al. reported that high significance between a
single-nucleotide polymorphism on the PinX1 gene and
lower bladder cancer risk [12]. However, the biological
function of PinX1 on UCB tumorigenesis and tumor
progression has not been characterized. In this study, we
investigated the clinicopathological and prognostic sig-
nificance as well as the potential role of PinX1 in the de-
velopment and progression of UCB.Table 1 Correlation of PinX1 expression in tissue with patient
PinX1 expression

























aChi-square test. bmean age. UCB: urothelial carcinoma of bladder.Materials and methods
Patient information and tissue microarray
To prepare of the bladder tissue microarray (TMA), 187
patients with UCB that had undergone RC were selected
from the surgical pathology archives of the Department
of Pathology of the Sun Yat-Sen University Cancer Center,
the First Affiliated Hospital of Sun Yat-Sen University, and
Guangdong Provincial People’s Hospital between 1999
and 2008. The median follow-up time was 92 months
(range 8–156 months) and the clinicopathological charac-
teristics are summarized in Table 1. Prior patient consent
and approval from the Institutional Research Ethics Com-
mittee were obtained for the use of these clinical materials
for research purposes. The tumor specimens were ob-
tained from the paraffin blocks of 187 primary UCBs. We
also obtained 102 samples, in paraffin blocks, of normal
bladder mucosa in adjacent non-neoplastic bladder tissue
from the same UCB patients. The TMA was constructed
according to a method described previously [13]. In our
constructed bladder tissue TMA, three sample cores weres’ clinicopathological variables in 187 cases of UCB
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sue. Multiple sections (5-μm thick) were obtained from
the TMA block and mounted on microscope slides.
Tumor grade and stage were defined according to the cri-
teria of the World Health Organization and the sixth edi-
tion of the TNM classification of the International Union
Against Cancer (UICC, 2002).Immunohistochemistry
Immunohistochemistry (IHC) studies were performed
using a standard streptavidin-biotin-peroxidase complex
method [14,15]. TMA slides were dried overnight at
37°C, dewaxed in xylene, rehydrated with graded alcohol,
and immersed in 3% hydrogen peroxide for 20 min to
block endogenous peroxidase activity. Antigen retrieval
was carried out in a microwave oven with 10 mM citrate
buffer (pH 6.0) for 15 min. The slides were incubated with
10% normal goat serum at room temperature for 10 min
to reduce nonspecific reactions. Subsequently, the TMA
slides were incubated overnight at 4°C with rabbit poly-
clonal antibody against PinX1 (1:200; Proteintech Group,
USA), mouse monoclonal anti-Ki-67 (1:100; Sigma-
Aldrich, USA), or mouse monoclonal anti-p16 (1:100; Cell
Signaling Technology, USA) and anti-cyclin D1 (1:100;
Cell Signaling Technology, USA), overnight at 4°C. After
rinsing five times with 0.01 mol/L phosphate-buffered
saline (PBS; pH 7.4) for 10 min, primary antibody was
detected using a secondary antibody (Envision; Dako,
Glostrup, Denmark) for 1 h at room temperature and
stained with 3,3-diaminobenzidine (DAB) after washing in
PBS again. Finally, the sections were counterstained with
Mayer’s hematoxylin, dehydrated, and mounted.
Two independent pathologists blinded to the clinico-
pathological information performed the analysis of IHC
for PinX1. Similar to that observed in other human tis-
sues [16,17], positive expression of PinX1 in epithelial
cells of bladder tissues was primarily in nuclear pattern.
PinX1 immunoreactivity was classified into two groups
as previously described [17]: negative expression, when
PinX1 positive cells were less than 50%; and positive ex-
pression, when at least 50% of the cells showed positive
staining of PinX1. For the Ki-67 labeling index, the pro-
portion of positive cells in the stained sections was eval-
uated at × 200 magnification and the mean value of 10
representative fields analyzed from each section was re-
corded. Previous scoring criterions were used for evalu-
ation of the p16 and cyclin D1 IHC staining [18,19].UCB cell lines and cell cultures
The UCB cell lines EJ, T24, and 5637 were cultured in
RPMI 1640 (Invitrogen, USA) supplemented with 10%
fetal bovine serum (HyClone, USA). All cells were grown
in a humidified incubator at 37°C with 5% CO2.Paired tumor and adjacent tissues
Ten pairs of UCB tissues and matched adjacent, mor-
phologically normal bladder epithelial tissues were
frozen and stored in liquid nitrogen until used to
compare the expression levels of PinX1 mRNA and
protein.RNA extraction and quantitative real-time polymerase
chain reaction (qRT-PCR)
Total RNA was isolated from the 10 pairs of UCB tis-
sue and normal bladder tissue using TRIZOL reagent
(Invitrogen, USA). RNA was reverse-transcribed using
SuperScript First Strand cDNA System (Invitrogen, USA)
according to the manufacturer’s instructions. The PinX1
sense primer was 5'-ATGTCTATGCTGGCTGAA-3',
and the antisense primer was 5'-TCTGTGGCTCCTT
GCT-3'. For the GAPDH gene, the sense primer was
5'- CCCACATGGCCTCCAAGGAGTA -3', and the
antisense primer was 5'- GTGTACATGGCAACTGT
GAGGAGG -3'. qRT-PCR was done using SYBR
Green PCR master mix (Applied Biosystems, USA) in
a total volume of 20 μl on the 7900HT fast Real-time
PCR system (Applied Biosystems, USA) as follows: 50°C
for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s, and
60°C for 60 s. A dissociation procedure was performed to
generate a melting curve for confirmation of amplification
specificity. GAPDH was used as the reference gene.
The relative levels of gene expression were represented as
ΔCt = Ctgene- Ctreference, and the fold change of gene ex-
pression was calculated by the 2-ΔΔCt Method. Experiments
were repeated in triplicate.Western blotting
Equal amount of whole-cell lysates were resolved with
sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and transferred to a polyvinylidene difluoride
membrane (Pall Corp., USA). This was followed by
incubation with primary rabbit polyclonal antibody
against human PinX1 (Proteintech Group, USA),
mouse monoclonal antibodies to p16 (Cell Signaling
Technology, USA), cyclin D1 (Cell Signaling Technology,
USA), CDKN2B (Cell Signaling Technology, USA), CCND2
(Cell Signaling Technology, USA), rabbit monoclonal
antibodies GADD45A (Santa Cruz Biotechnology, USA),
ANAPC2 (Santa Cruz Biotechnology, USA), and CDK5R1
(Santa Cruz Biotechnology, USA), respectively. The
immunoreactive proteins were detected with enhanced
chemiluminescence detection reagents (Amersham
Biosciences, Sweden) according to the manufacturer’s
instructions. The membranes were stripped and re-
blotted with a mouse monoclonal anti-GAPDH anti-
body (Santa Cruz Biotechnology, USA) as a loading
control.
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The PinX1 expression construct was generated by sub-
cloning the PCR-amplified human PinX1 coding sequence
into the pBABE retroviral vector. The construction of the
PinX1 short hairpin RNA (shRNA) lentiviral expression
vector and retroviral production and infection have been
described previously [11,17]. Based on their baseline ex-
pression of PinX1, UCB cells were transduced with either
pBABE/PinX1 or pSUPER-retro-PinX1-shRNA. EJ and
T24 cells showed low expression of PinX1 and they were
infected with retroviruses carrying pBABE/PinX1. The
5637 cells showed had high expression of PinX1 and they
were infected with retroviruses carrying pSUPER-retro-
PinX1-shRNA.
Cell proliferation assay and colony-forming assay
For cell proliferation assays, cells were reseeded in
96-well plates at 2 × 103 cells/well 24 h after transfection
and incubated overnight in 100 μL of culture medium.
Then, 20 μL of 5 mg/mL 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich,
USA) was added to the wells and cells were incubated at
37°C for 4 h. The supernatant was removed, and 150 μL
dimethyl sulfoxide was added to the wells. After incu-
bating at 37°C for 15 min, absorbence at 570 nm wasFigure 1 The expression of PinX1 in UCB and adjacent normal bladde
examined by qRT-PCR in 8/10 UCB cases, when compared with adjacent n
Error bars, SD calculated from three parallel experiments. (B) Down-regulat
7/10 UCB cases, when compared with adjacent normal bladder tissues. Exp
PinX1 in UCB and adjacent normal bladder tissues by IHC (100×). An UCB (
adjacent normal bladder urothelial mucosal tissue was positive stained by
by PinX1 in the nucleus (D). Negative expression of PinX1 was observed in
demonstrated a nuclear staining of PinX1 (E). An UCB (case 126) was negameasured with a microplate reader (SpectraMax M5,
Molecular Devices, USA).
For colony-forming assays, cells were reseeded at 500
or 1000 cells/well in 6-well plates at 24 h after transfec-
tion, with medium replacement every three days. After
incubating at 37°C for 2–3 weeks, cells were fixed and
stained with crystal violet.
Flow cytometry
For cell cycle analysis, cells were collected at the indicated
time points. Cells (1 × 106) were washed with PBS and fixed
with cold 70% ethanol at 4°C overnight. Then, cells were
treated with RNase and stained with propidium iodide (PI,
Sigma-Aldrich, USA). The DNA content of the cells was
quantified using a flow cytometer (Epics Elite, Beckman
Coulter, USA). In total, 10,000 nuclei were examined in the
flow cytometer, and DNA histograms were analyzed by
ModFit software (Verity Software House, USA).
For apoptosis analysis, cells transfected with above
mentioned formulations were stained with annexin V-PE
and propidium iodide (PI) 48 h post-transfection using
the Annexin V apoptosis detection kit (BD biosciences,
USA). The percentage of apoptotic cells was quantified
by flow cytometry. Viable cells are both Annexin V-PE
and PI negative.r tissues. (A) Down-regulated expression of PinX1 mRNA was
ormal bladder tissues. Expression levels were normalized for GAPDH.
ed expression of PinX1 protein was detected by Western blotting in
ression levels were normalized with GAPDH. (C-F) The expression of
case 45) tissue showed negative expression of PinX1 (C), while its
PinX1, in which more than 90% of tumor cells were positively stained
another UCB tissue (case 73), in which only 10% of tumor cells
tively stained by PinX1 (F).
Table 2 Univariate analysis of factors associated with
overall survival of 187 patients with UCB
Variable All cases RR (95% CI) P valuea
Age(years) 0.309
≤60b 80 1
>60 107 1.332 (0.767-2.315)
Gender 0.648
Male 166 1
Female 21 0.807 (0.321-2.026)
Tumor multiplicity 0.676
Unifocal 79 1
Multifocal 108 1.443 (0.852-2.471)
WHO grade 0.022
G1 46 1
G2 66 2.304 (0.968-5.485)
G3 75 3.206 (1.396-7.363)
pT status <0.001
pT1 35 1
pT2 95 1.535 (0.890-2.653)
pT3 37 3.025 (1.242-7.363)
pT4 20 7.457 (2.950-18.847)
pN status <0.001
pN- 157 1
pN+ 30 8.904 (5.056-15.681)
PinX1 <0.001
Negative expression 83 5.148 (2.708-9.786)
Positive expression 104 1
aChi-square test. bmean age. RR: relative risk. CI: confidence interval.
UCB: urothelial carcinoma of bladder.
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The telomerase activity was examined when the cells at
the 15 passage. Telomerase activity was measured with
the TRAPeze telomerase detection kit (Chemicon, USA).
PCR products were separated by electrophoresis on a
12.5% nondenaturing polyacrylamide gel, visualized
by SYBG green (Invitrogen, USA) staining and semi-
quantitated according to the manufacturer’s instruction.
Briefly, telomerase activity consists of the intensity of
the TRAP product band and the processivity of TRAP
ladders.
Telomere lengths analysis
The telomere length was examined when the cells at the
15 passage. Two micrograms of gemonic DNA from tissue
extracts were doubly digested with Hinf I and Rsa I over-
night at 37°C. The DNA products of enzymes digestion
were electrophoresed on 0.8% agarose gel, and transferred
onto a nylon membrane for hybridization with digosin-labbed (TTAGGG)3 oligos. The hybridization signal was
detected by the AP-conjugated anti-digosin antibodies
(Roche Diagnostics, Indianapolis, Indiana, USA) and im-
aged by CDP-Star (Roche, Switzerland).
In vivo tumorigenicity assays
In total, male BALB/c nu/nu immune deficient mice
(6 weeks old, 18–20 g) were purchased from Shanghai
Slac Laboratory Animal Co., Ltd. (Shanghai, China). The
mice were housed in barrier facilities on a 12 h light/
dark cycle. All experimental procedures were approved
by the Institutional Animal Care and Use Committee of
Sun Yat-Sen University. Cells (5 × 106 EJ-Vector, 5 × 106
EJ-PinX1, 5 × 106 T24-Vector, 5 × 106 T24-PinX1, 5 × 106
5637-Scramble, 5 × 106 5637-PinX1-shRNA) were suspen-
ded in RPMI 1640 medium and injected subcutaneously
into the flank of mice. The tumor diameter was measured
and the volume (width2 × length × 0.52) calculated every
other day. Mice were humanely killed on day 48, and the
tumors were dissected and weighed.
Statistical analysis
Data were analyzed using SPSS16.0 software (SPSS Inc.).
Significant associations between PinX1 expression and
clinicopathological parameters were assessed using a χ2
test. Survival curves were plotted by Kaplan–Meier ana-
lysis and compared by the log-rank test. Cox regression
analysis was carried out to assess the significance of vari-
ables for survival. Data were expressed as mean ± SD, and
the t-test was used to determine the significance of differ-
ences between two groups. All tests carried out were two-
sided. P < 0.05 was considered statistically significant.
Results
qRT-PCR and Western blotting analysis of PinX1
expression in bladder tissues
Our qRT-PCR results showed that PinX1 mRNA ex-
pression was downregulated in eight out of 10 UCB
samples compared with the paired normal bladder tissues
(Figure 1A). Western blotting analyses also demonstrated
downregulation of the PinX1 protein in seven out of 10
UCB samples as compared to their normal counterparts
(Figure 1B).
IHC analysis of PinX1 expression in TMA of
bladder tissues
The expression of PinX1 protein was determined by
IHC in a TMA containing 187 cases of UCBs and 102
specimens of adjacent normal bladder tissues. Using the
criteria described earlier, negative expression of PinX1
was detected in 44.4% (83/187) of UCBs, while only
20.6% (21/102) of normal bladder tissues had negative
staining (Figure 1C-1F, P = 0.004, χ2 test for trend).
Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 Kaplan-Meier survival analysis of PinX1 expression in patients with UCB (log-rank test). (A) Total, probability of overall survival of
all patients with UCB: negative expression (dashed line), n = 83; positive expression (solid line), n = 104. (B) Adjuvant chemotherapy, probability of
recurrence-free survival of patients underwent adjuvant chemotherapy with UCB: negative expression (dashed line), n = 27; positive expression
(solid line), n = 20. (C) G1, probability of overall survival of G1 patients with UCB: negative expression (dashed line), n = 19; positive expression (solid
line), n = 27. (D) G2, probability of overall survival of G2 patients with UCB: negative expression (dashed line), n = 29; positive expression (solid line),
n = 37. (E) G3, probability of overall survival of G3 patients with UCB: negative expression (dashed line), n = 35; positive expression (solid line), n = 40.
(F) pT1, probability of overall survival of pT1 patients with UCB: negative expression (dashed line), n = 13; positive expression (solid line), n = 22.
(G) pT2, probability of overall survival of pT2 patients with UCB: negative expression (dashed line), n = 38; positive expression (solid line), n = 57.
(H) pT3, probability of overall survival of pT3 patients with UCB: negative expression (dashed line), n = 20; positive expression (solid line), n = 17.
(I) pT4-, probability of overall survival of pT4 patients with UCB: negative expression (dashed line), n = 12; positive expression (solid line), n = 8.
(J) pN-, probability of overall survival of pN- patients with UCB: negative expression (dashed line), n = 64; positive expression (solid line), n = 93.
(K) pN+, probability of overall survival of pN+ patients with UCB: negative expression (dashed line), n = 19; positive expression (solid line), n = 11.
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clinicopathological features
The association between PinX1 expression in UCB de-
tected by IHC and several known clinicopathological
features were studied further. PinX1 levels were in-
versely correlated with tumor multiplicity and advanced
N classification (P < 0.05, Table 1). A significant cor-
relation between the Ki-67 labeling index and PinX1 ex-
pression in UCB was also found (P = 0.004, Table 1).
There was no significant association between PinX1 ex-
pression and other clinicopathological features, such as
patient gender, age, tumor grade, and pT classification
(P > 0.05, Table 1).
Relationship between clinicopathological variables,
PinX1 expression, and UCB patient survival: univariate
survival analysis
First, to confirm the representativeness of the UCB in
our study, we analyzed the established prognostic pre-
dictors of survival in our cohort. Kaplan–Meier ana-
lysis demonstrated a significant impact of well-known
clinicopathological prognostic parameters on patient
survival, such as tumor grade, pT status and pN status
(P < 0.05, Table 2). Assessment of survival in total
UCBs determined that the positive expression of PinX1
was correlated with superior survival (P < 0.001, Table 2,
Figure 2A).
Moreover, we analyzed the recurrence-free survival of
patients who received adjuvant chemotherapy. Interest-
ingly, we found that patients with negative PinX1 ex-
pression had a much higher risk of recurrence than did
patients with positive PinX1 expression. As shown inTable 3 Multivariate analysis of prognostic factors on overall
Variable Hazards ratio
WHO grade ( G1 vs G2 vs G3) 1.045
pT status ( pT1 vs pT2 vs pT3 vs pT4) 2.483
pN status ( pN- vs pN+) 7.169
PinX1 ( Positive vs Negative) 4.122
CI: confidence interval.Figure 2B, the 5-years recurrence-free survival rate was
only 19.0% in the PinX1-negative group, whereas it dra-
matically increased to 70.0% in the PinX1- positive
group (log-rank test, P = 0.001, Figure 2B).
Furthermore, stratified survival analysis determined that
PinX1 expression could differentiate the survival of the
UCB patients with grades 1, 2, and 3 tumors (P=0.020, < 0.001,
and 0.021, respectively, Figure 2), as well as with pT1
(P = 0.006), pT2 (P = 0.003), pT3 (P = 0.003), and pN-
(P < 0.001) classifications (Figure 2).
Independent prognostic factors of UCB: multivariate Cox
regression analysis
The expression of PinX1 as well as other clinical patho-
logical parameters that were significant in univariate
analysis (grade, pT stage, pN stage), was further exam-
ined in multivariate analysis. Negative expression of
PinX1 was found to be an independent prognostic factor
for poor overall survival (relative risk: 4.122, 95% confi-
dence interval: 2.152–7.896, P < 0.001, Table 3). Of the
other parameters, pT stage, and pN stage were also dem-
onstrated as independent prognostic factors for overall
survival (P < 0.05, Table 3).
PinX1 inhibits proliferation and clonogenicity of UCB cells
The stable PinX1-expressing cell lines EJ-PinX1 and
T24-PinX1 were established (Figure 3A and 3B) to study
the biological role of PinX1 in UCB growth/proliferation.
Western blotting revealed that PinX1 protein was highly
expressed in the EJ-PinX1 and T24-PinX1 cells, whereas
expression low or not detected in the stable EJ-Vector
and T24-Vector control cell lines, respectively. In thesurvival (Cox regression model)





Figure 3 PinX1 inhibited growth and proliferation of UCB cells in vitro. (A-B) Ectopic expression of PinX1 in EJ and T24 cell analyzed by
western blotting. GAPDH was used as a loading control. (C-D) Ectopic expression of PinX1 inhibited EJ and T24 cell proliferation in MTT assays.
Each bar represents the average ± SD of three independent experiments. (E-F) Upregulation of PinX1 inhibited EJ and T24 cell growth in colony
formation assays. Representative micrographs (upper) and quantification (lower) of crystal violet-stained cells. (G) RNAi-silencing of PinX1 in
shRNA-transduced stable 5637 cell. GAPDH was used as a loading control. (H) Silencing endogenous PinX1 promoted cell growth as determined
by MTT assays. Each bar represents the average ± SD of three independent experiments. (I) Downregulation of PinX1 promoted 5637 cell growth
in colony formation assays. Representative micrographs (upper) and quantification (lower) of crystal violet-stained cells. *P < 0.05, **P < 0.01.
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slowly, with 1.4-fold and 1.7-fold fewer cells than the
EJ-Vector and T24-Vector control cells respectively, by
day 5 after plating (Figure 3C and 3D). In the colony-
formation assay, EJ-PinX1 and T24-PinX1 cells also
formed fewer and smaller colonies than the EJ-Vector
and T24-Vector cells, respectively. (Figure 3E and 3F).
Furthermore, knocking-down of endogenous PinX1 in
5637 cells by shRNA significantly decreased PinX1 pro-
tein expression (Figure 3G) and increased 5637 cell via-
bility, as analyzed by the MTT and colony-formation
assays (Figure 3H and 3I).PinX1 inhibits xenografted tumor growth in vivo
Tumors formed from EJ-PinX1 and T24-PinX1 cells im-
planted in nude mice grew more slowly and weighed
substantially less than those formed by EJ-Vector and T24-
Vector cells respectively, after 48 days (Figure 4A and 4B).
Furthermore, tumors derived from 5637 cells trans-
duced with retroviruses expressing PinX1-shRNA grewmuch faster and weighed significantly more at day 48
than those formed by 5637-Scramble cells (Figure 4C).
Effect of PinX1 on UCB cell apoptosis measured by
flow cytometry
Cellular apoptosis was examined by the Annexin-V/PI
method in UCB cells. Annexin V binds to those cells
that express phosphatidylserine on the outer layer of the
cell membrane, which is a characteristic feature of cells
entering the process of apoptosis. Apoptosis was then
quantified by the method of flow cytometry. The in-
cidences of apoptotic death in EJ and T24 cells were
increased by the upregulated expression of PinX1
(Additional file 1: Figure S1A and Figure S1B).
Conversely, PinX1 silencing decreased the incidence of
apoptotic death in 5637 cells (Additional file 1: Figure S1C).
Effect of PinX1 on telomerase activity and telomere
length in UCB cells
As it has been documented that PinX1 could inhibit
telomerase activity, shorten telomeres, and suppress
Figure 4 PinX1 inhibited growth and proliferation of UCB cells in vivo. (A-B) Ectopic expression of PinX1 in EJ and T24 cells dramatically
inhibited tumor growth and proliferation in vivo as determined by a subcutaneous xenograft mice model. Representative graph of tumor growth
(left). Data points are the mean tumor volumes ± SD (middle) and mean tumor weights (right) 48 days after inoculation. (C) Suppression of PinX1
in 5637 cells promoted tumor growth and proliferation in vivo as determined by a subcutaneous xenograft mice model. Representative graph of
tumor growth (left). Data points are the mean tumor volumes ± SD (middle) and mean tumor weights (right) 48 days after inoculation. **P < 0.01.
Liu et al. Molecular Cancer 2013, 12:148 Page 9 of 14
http://www.molecular-cancer.com/content/12/1/148tumor growth [20,21], we investigated whether PinX1
could influence tumor growth by regulating telomerase
activity and the telomere length pathway. Indeed, we
found that overexpression of PinX1 decreased telomerase
activity and shortened telomeres in EJ and T24 cells
(Figure 5A and 5B).
By contrast, reduced PinX1 by PinX1-shRNA transfec-
tion increased telomerase activity and elongated telomere
length in 5637 cells (Figure 5C).
PinX1 regulates G1/S phase transition of the cell cycle
Upregulation of PinX1 expression in EJ and T24
cells significantly increased the proportion of cells in
the G0/G1 phase and decreased those in the S phase
(Figure 6A and 6B).
Conversely, downregulation of PinX1 in 5637 cells
clearly decreased the proportion of cells in the G0/G1
phase and increased those in the S phase (Figure 6C).
These findings indicate that PinX1 may play an important
role in regulating G1 to S phase transition in UCB cells.
PinX1 regulated p16 and cyclin D1 expression in UCB cells
To gain further insight into the functions of PinX1 in
UCB cell growth and development, the mRNA expressionprofiles of T24-PinX1 cells were compared with that of
T24-Vector using a Human Cell Cycle RT2 ProfilerCC
PCR Array containing 84 cell cycle related genes. The re-
sults showed that a total of six up-regulated and five
down-regulated genes (> 1.5-fold) were identified in T24-
PinX1 cells compared with that in T24-Vector cells
(Additional file 2: Table S1). Subsequently, CDKN2A (i.e.
p16), CDKN2B (i.e. p15), GADD45A, CCND1 (i.e. cyclin
D1), CCND2 (i.e. cyclin D2), ANAPC2, and CDK5R1,
which exhibited > 2-fold mRNA differences before and
after PinX1 overexpressed (Figure 6D), were selected
and further analyzed by western blotting. Consistent
with that of mRNA expression in real-time PCR
array, increased protein expression of p16 and de-
creased protein expression of cyclin D1 were examined
by western blotting in T24 cells after PinX1 overexpressed
(Figure 6E).
Expression of p16 and cyclin D1 in UCB tissues and their
correlation with PinX1 expression
Utilizing the previous scoring criterions for IHC staining
evaluation of p16 and cyclin D1 [18,19], there was posi-
tive expression of p16 and cyclin D1 in 90/187 (48.1%)
and 102/187 (54.5%) of UCBs, respectively. In addition,
Figure 5 Effect of PinX1 on telomerase activity and telomere length in UCB cells. Telomerase activity was measured by TRAP assays and
Southern blot analysis of telomeric terminal restriction fragments were used for determination of the telomere length. (A) Overexpression of
PinX1 in EJ cells decreased telomerase activity and shortened telomere length. (B) Overexpression of PinX1 in T24 cells decreased telomerase
activity and shortened telomere length. (C) RNAi-silencing of PinX1 in 5637 cells increased telomerase activity and elongated telomere length.
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and p16 was evaluated in our UCB cohort, in which the
frequency of cases with negative PinX1 expression was
significantly higher in negative p16 expression cases
(54/97 cases, 55.7%) than in positive p16 expression ones
(29/90 cases, 32.2%) (P = 0.001, Additional file 3: Table S2).
A significant correlation between the expression of PinX1
and cyclin D1 was also observed in the UCB tissues
(P < 0.001, Additional file 3: Table S2).
Discussion
It has been proposed that the PinX1 gene could be a pu-
tative tumor suppressor gene and/or therapeutic target
for human cancers [11,20,21]. Although the relationship
between the PinX1 gene and human tumors has beenstudied widely, such as in medulloblastoma, hepato-
celllular carcinoma, prostate cancer, and gastric cancer
[15,22-25], the expression and prognostic value of PinX1
protein has not been investigated in UCB. In addition,
the molecular mechanisms underlying the potential role
of PinX1 in UCB remain unknown. In this study, we
examined the expression dynamics status of PinX1 firstly
by IHC using a TMA containing a series of UCB and ad-
jacent morphologically normal bladder epithelial tissues.
The IHC results demonstrated that negative expression
of PinX1 protein in 44.4% of primary bladder tumor, but
in only 20.6% of normal bladder epithelial tissues. In
addition, western blotting revealed downregulated ex-
pression of PinX1 in the majority of UCBs when com-
pared with their adjacent normal bladder epithelial tissues.
Figure 6 PinX1 regulates the G1/S phase transition and cell proliferation through the p16/cyclin D1 pathway in UCB cells. Flow
cytometric analysis of the (A) EJ bladder urothelial carcinoma cells infected with vector or PinX1, (B) T24 bladder urothelial carcinoma cells
infected with vector or PinX1, and (C) 5637 cells infected with RNAi-vector or PinX1-shRNA. (D) The seven genes, CDKN2A (i.e. p16), CDKN2B
(i.e. p15), GADD45A, CCND1 (i.e. cyclin D1), CCND2 (i.e. cyclin D2), ANAPC2 and CDK5R1), were examined >2-fold mRNA differential expression in
PinX1-transfected T24 cells compared with that of scramble vector transfected by using a Human Cell Cycle RT2 ProfilerCC PCR Array. (E) Overex-
pression of PinX1 substantially upregulated p16 expression and downregulated cyclin D1 expression in T24 cells detected by western blotting.
*P < 0.05, **P < 0.01.
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led to the inhibition of cell proliferation and tumourigeni-
city in vitro and in vivo, accompanied with G1/S phase
arrest, upregulation of p16 expression, downregulation of
cyclin D1 expression, as well as the deactivation of tel-
omerase activity. Meanwhile, RNA interference silencing
of PinX1 expression induced opposite results. These find-
ings provide evidence for the concept that downregulating
the expression of PinX1 may play an important role in the
tumorigenic process of UCB.
Further correlation analyses demonstrated that negative
expression of PinX1 in our UCB cohort was significantly
associated with advanced N classification, higher prolifera-
tion index, and tumor multiplicity. Importantly, we foundthat decreased or depleted expression of PinX1 was asso-
ciated with poor prognosis and reduced survival periods
for UCB patients. Multivariate analysis showed that the
loss of PinX1 protein expression could be used as an inde-
pendent prognostic predictor for UCB patients. Further-
more, in stratified survival analysis, PinX1 expression
could differentiate the survival of certain subsets of UCB
patients, including patients with grade 1, 2 and 3 tumors
and at pT1, pT2, pT3, and pN- stage. Our results indicate
that the expression level of PinX1 protein might provide
useful information in the evaluation prognosis and follow-
up schedule guiding for UCB patients.
PinX1 is an evolutionarily conserved nuclear protein
that has been demonstrated to be a telomerase/telomere-
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fied as an intrinsic telomerase inhibitor and a putative
tumor suppressor because of its binding to and inhibition
of telomerase [20]. Recently, it has been reported that hu-
man PinX1 can regulate telomerase activity and suppress
tumor growth both in vivo and in vitro [20,21]. Overex-
pression of PinX1 in tumor cells could inhibit telomerase
activity, shorten telomeres, and suppress tumor growth,
while depletion of endogenous PinX1 increased telo-
merase activity, elongated telomeres, and enhanced
tumorigenicity in telomerase-positive HT1080 cancer cells
[20]. Disruption of the PinX1-dependent telomere main-
tenance pathway could reduce carcinogenesis and en-
hance chemotherapeutic sensitivity in telomerase-positive
human cancer cells as well [11]. In the present study, we
found that overexpression of PinX1 by transfection of
pBABE-PinX1 into EJ and T24 cells significantly reduced
cell growth, and arrested cells in the G0/G1 phase via the
inhibition of telomerase activity and shortening of telo-
meres. In contrast, inhibition of PinX1 expression by
shRNA transfection in 5637 cells promoted cell growth/
proliferation in vitro and vivo via by enhancing telomerase
activity and telomere elongating. These findings suggest
that PinX1 acts as an intrinsic telomerase inhibitor and ar-
rests cell growth in human UCB.
We showed that PinX1 could prohibit G1/S phase transi-
tion, to gain further insight into the downstream molecular
events involving PinX1 and UCB growth/proliferation, we
compared mRNA expression profiles between T24-PinX1
and T24-Vector cells using a Human Cell Cycle real-time
PCR array containing 84 well-known cell cycle related
genes. Of the 84 genes, 7 genes were differentially expressed
by 2-fold or more (i.e. upregulated: CDKN2A (i.e. p16),
CDKN2B (i.e. p15) and GADD45A; downregulated:
CCND1 (i.e. cyclin D1), CCND2 (i.e. cyclin D2), ANAPC2
and CDK5R1). Subsequently, protein expression of these
seven genes was analyzed by western blotting. Consistent
with that of mRNA expression in the real-time PCR array,
upregulated p16 expression and downregulated cyclin D1
expression were validated in the protein level following
PinX1 overexpression in T24 cells. It was appear that
PinX1 regulated the cell cycle and influenced cell growth/
proliferation via the regulation of p16 and cyclin D1 ex-
pression in the UCB cells we used. Further, the status of
p16 and cyclin D1 expression was examined by IHC in a
TMA of a large cohort of UCBs. Our analysis demon-
strated that there were significant positive correlations be-
tween the expression of PinX1 and p16 and between the
expression of PinX1 and cyclin D1, which confirmed the
results observed in the T24 cells.
The p16 protein acts as an inhibitor of cell prolifera-
tion by competitively binding the cyclin-dependent kin-
ase (CDK)4/6 kinases against their regulator cyclin D1
and blocking phosphorylation of the retinoblastoma (Rb)protein, leading to cell cycle arrest [26]. The p16/cyclin
D1 pathway is one of the key signal transduction path-
ways at the G1/S checkpoint in the cell cycle [27,28].
Dysfunction of the proteins involved in the p16 pathway
such as deletion of the p16 gene and overexpression of
CDKs of cyclin D1 will lead to Rb phosphorylation, sub-
sequent progression of G1/S phase transition and pro-
motion of uncontrolled cell growth/proliferation [29-34].
Song et al. reported that the decrease of p16 cooperated
with cyclin D1 and the caused deregulation of G1/S
checkpoint, leading to abnormal cell proliferation in
nasopharyngeal carcinoma [35]. These observations, to-
gether with the results of our PinX1 functional studies
in the UCB cells, suggest that decreased expression of
PinX1 in UCB might be involved in the p16/cyclin D1
associated pathway and thus support cancer cell growth/
proliferation. Clearly, better understanding of the precise
molecular mechanisms of p16 and cyclin D1 regulated
by PinX1 may lead to more effective management of
UCB growth and/or progression.
Based on previous studies [20,21,26-28,35] and the
present study, we propose that PinX1 regulates UCB cell
proliferation through at least two distinct mechanisms.
In one mechanism, PinX1 influences UCB cell growth/
proliferation by binding to telomerase and inhibiting its
activity. In the other mechanism, PinX1 inhibites UCB
cell growth/proliferation by regulating the expression of
the key cell cycle genes for p16 and cyclin D1. More stud-
ies are needed to confirm these two mechanisms and to
elucidate whether other signaling pathways also contribute
to PinX1-mediated cell growth/proliferation in UCB.
In summary, we describe for the first time in this study
the protein expression pattern of PinX1 in UCB and adja-
cent morphologically normal bladder epithelial tissues. Our
results provide a basis for the concept that negative expres-
sion of PinX1 in UCB may be important in the acquisition
of an aggressive and/or poor prognostic phenotype. In
addition, the functional studies of PinX1 in this report sug-
gest a potential important role of PinX1 in the control of
cell growth/proliferation via the regulation of telomerase
activity and the p16/cyclin D1 pathway, an activity that
might be responsible, at least in part, for the development
and/or ultimately the progression of human UCB.
Additional files
Additional file 1: Figure S1. PinX1 promoted apoptosis of UCB cells.
(A) Ectopic expression of PinX1 promoted EJ cell apoptosis by Annexin-V/PI
method (P = 0.012). (B) Ectopic expression of PinX1 promoted T24 cell
apoptosis by Annexin-V/PI method (P = 0.013). (C) Sliencing endogenous
PinX1 inhibited 5637 cell apoptosis by Annexin-V/PI method (P = 0.005).
Additional file 2: Table S1. List of genes differentially expressed in T24
cells after PinX1 overexpression using a Human Cell Cycle Real-time PCR Array.
Additional file 3: Table S2. Association between expression of PinX1
and p16 and cyclin D1 in UCB.
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